Universal Peace Federation: 70 Years After the Korean War, UPF Holds Online Summit for Peace and Reconciliation
19.11.2020 14:52:00 EET | Business Wire | Press release
The Rally of Hope, the third organized by UPF, is expected to draw much international participation this weekend. This rally, produced in Korea, will focus mainly on the Korean peninsula, seventy years after the outbreak of the Korean war (1950-53). UPF is an NGO in general consultative status with the Economic and Social Council of the United Nations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201119005660/en/
The Little Angels’ performance to thank the countries that came to South Korea’s aid in commemoration of the 70th anniversary of the outbreak of the Korean War (Photo: Business Wire)
Remembering yesterday’s war heroes; highlighting today’s peacemakers
In addition to featuring prominent global leaders, the renowned Little Angels Folk Ballet of Korea will perform a special tribute in honor of veterans of the Korean War.
Dr. Hak Ja Han Moon, the co-founder of UPF, will be keynote speaker. Her husband, the late Reverend Moon, was liberated by UN forces from the North Korean death camp of Heungnam. In her memoirs, Mother of Peace, Mrs. Moon explains how she escaped death several times during this conflict.
Further speakers include current and former heads of state and government whose countries were part of the United Nations forces in the Korean War: Sahle-Work Zewde, president of Ethiopia, the only current female head of State in Africa; Yves Leterme, Prime Minister of Belgium (2009-2011); Stephen Harper Prime Minister of Canada (2006-2015), now chairman of the International Democrat Union.
Other speakers include current heads of state whose countries have overcome domestic tensions and progressed toward national reconciliation: Salva Kiir, President of South Sudan, who recently invited the UPF chairman to attend the signing of the Juba peace agreement; Uhuru Kenyatta, President of Kenya and Mahinda Rajapaska, Prime Minister of Sri Lanka.
Mr. Jacques Marion, president of UPF Europe-Middle East, remarked that the Rally of Hope sets a strong signal for a peaceful unification. The interfaith prayer by religious leaders, the presence of Veterans of the Korean war representing the conflicting armies, will testify and sound an appeal for reconciliation on the divided peninsula, he said.
UPF states on its website that a main objective is the “peaceful reunification of the Korean peninsula and harmonious relations among the nations of Northeast Asia.” Directed towards this goal, UPF strives to realize the vision of a global democratic society, driven by the free-market and centered on family-based universal values.
This rally will be a dazzling display of digital technology from the land of K‑pop. A live internet audience of millions will be joined by an interactive audience using various social media apps.
Rally of Hope - Live Broadcast:
Date: November 22, 2020, 1:30 AM - 3:30 AM CET
Participants: VIPs & guests from all over the world (register at: rallyofhope.eu)
Highlights of the Rally (Online):
November 22, 2020, 6:00 PM - 7:00 PM CET
Participants: VIPs & guests from all over Europe & Middle East
Public registration for the rally (live or highlights) at: rallyofhope.eu
Media direct live streaming will use: peacelink.live
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201119005660/en/
Contact information
Peter Zoehrer, UPF Media Relations - Europe & Middle East
Phone: +43 (0) 6645238794
media@europe.upf.org
Websites: UPF.ORG & EUME.UPF.ORG
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 08:30:00 EEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom